RxDoctor Payments Data

Alex Tran, MD

Family Medicine · Whittier, CANPI 1437259348

Payments from drug & device makers

$619in general payments, 2019–2025

Across 33 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$140
  • AbbVie$87
  • Novo Nordisk$73
  • Lilly USA, LLC$54
  • Karyopharm Therapeutics Inc.$26
  • Otsuka America Pharmaceutical, Inc.$24
  • plus $215 from 12 others

What the payments were for

  • Food & beverage$619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$619 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$60,110
Medicare patients
183
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$173,234
OzempicSemaglutide118$113,099
EliquisApixaban85$73,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$59,522
TrulicityDulaglutide39$43,965
TradjentaLinagliptin47$40,367
JanuviaSitagliptin Phosphate24$25,629
Breo ElliptaFluticasone/Vilanterol42$19,015
EntrestoSacubitril/Valsartan24$18,584
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$15,910
XareltoRivaroxaban11$13,637
Atorvastatin Calcium734$12,167
TrintellixVortioxetine Hydrobromide16$10,490
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm52$9,114
Tresiba Flextouch U-100Insulin Degludec14$7,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$19$213,600201 claims
Novo NordiskOzempic$73$113,099118 claims
GSKTrelegy Ellipta, Breo Ellipta$140$78,538131 claims
Lilly USA, LLCTrulicity, Humulin 70-30$54$53,07891 claims
MerckJanuvia$20$25,62924 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$10,49016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →